Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy

Molecular Therapy

Volumn 19, Issue 8, 2011, Pages 1468-1477

  Cutrera, Jeffry ^a   Dibra, Denada ^a   Xia, Xueqing ^a   Hasan, Azeem ^b   Reed, Scott ^c   Li, Shulin ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GENE PRODUCT; HYBRID PROTEIN; INTERLEUKIN 12; PLASMID DNA; UNCLASSIFIED DRUG; VALYLASPARAGINYLTHREONYLALANYLASPARAGINYLSERYLASPARAGINE INTERLEUKIN 12 FUSION PROTEIN; VIMENTIN;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE INSERTION; LIVER CARCINOMA; LIVER TOXICITY; LUNG METASTASIS; MASS SPECTROMETRY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REPORTER GENE; SECRETED ALKALINE PHOSPHATASE REPORTER GENE; SQUAMOUS CELL CARCINOMA; STOP CODON; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; WILD TYPE;

EID: 79961022478     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.38     Document Type: Article

References (34)

1. Kobayashi, M, Fitz, L, Ryan, M, Hewick, RM, Clark, SC, Chan, S et al. (1989). Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170: 827-845. (Pubitemid 19226667)
2. Del Vecchio, M, Bajetta, E, Canova, S, Lotze, MT, Wesa, A, Parmiani, G et al. (2007). Interleukin-12: biological properties and clinical application. Clin Cancer Res 13: 4677-4685. (Pubitemid 47294773)
3. Halin, C, Rondini, S, Nilsson, F, Berndt, A, Kosmehl, H, Zardi, L et al. (2002). Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 20: 264-269. (Pubitemid 34205419)
4. Dela Cruz, JS, Trinh, KR, Morrison, SL and Penichet, ML (2000). Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J Immunol 165: 5112-5121.
5. Dickerson, EB, Akhtar, N, Steinberg, H, Wang, ZY, Lindstrom, MJ, Padilla, ML et al. (2004). Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin. Mol Cancer Res 2: 663-673.
6. Colombo, G, Curnis, F, De Mori, GM, Gasparri, A, Longoni, C, Sacchi, A et al. (2002). Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 277: 47891-47897. (Pubitemid 36159317)
7. Li, S, Zhang, L, Torrero, M, Cannon, M and Barret, R (2005). Administration routeand immune cell activation-dependent tumor eradication by IL12 electrotransfer. Mol Ther 12: 942-949. (Pubitemid 41614490)
8. Yamazaki, M, Zhang, R, Straus, FH, Messina, M, Robinson, BG, Hashizume, K et al. (2002). Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Ther 9: 64-74. (Pubitemid 34145169)
9. Okada, Y, Okada, N, Mizuguchi, H, Takahashi, K, Hayakawa, T, Mayumi, T et al. (2004). Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma. Biochim Biophys Acta 1670: 172-180. (Pubitemid 38229768)
10. Gao, JQ, Eto, Y, Yoshioka, Y, Sekiguchi, F, Kurachi, S, Morishige, T et al. (2007). Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J Control Release 122: 102-110. (Pubitemid 47284554)
11. Wang, H, Chen, K, Cai, W, Li, Z, He, L, Kashefi, A et al. (2008). Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein. Mol Cancer Ther 7: 1044-1053.
12. Maeda, H, Fang, J, Inutsuka, T and Kitamoto, Y (2003). Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 3: 319-328. (Pubitemid 36293960)
13. Craig, R, Cutrera, J, Zhu, S, Xia, X, Lee, YH and Li, S (2008). Administering plasmid DNA encoding tumor vessel-anchored IFN-alpha for localizing gene product within or into tumors. Mol Ther 16: 901-906. (Pubitemid 351587100)
14. Work, LM, Büning, H, Hunt, E, Nicklin, SA, Denby, L, Britton, N et al. (2006). Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther 13: 683-693.
15. Dandachi, N, Hauser-Kronberger, C, Moré, E, Wiesener, B, Hacker, GW, Dietze, O et al. (2001). Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. J Pathol 193: 181-189. (Pubitemid 32118129)
16. Matos, JM, Witzmann, FA, Cummings, OW and Schmidt, CM (2009). A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States. J Surg Res 155: 237-243.
17. Moisan, E and Girard, D (2006). Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis. J Leukoc Biol 79: 489-498. (Pubitemid 44831226)
18. Ngan, CY, Yamamoto, H, Seshimo, I, Tsujino, T, Man-i, M, Ikeda, JI et al. (2007). Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br J Cancer 96: 986-992. (Pubitemid 46452285)
19. Wang, Z, Li, Y, Kong, D, Banerjee, S, Ahmad, A, Azmi, AS et al. (2009). Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69: 2400-2407.
20. Cutrera, J, Dibra, D, Xia, X and Li, S (2010). Enhancement of reporter gene detection sensitivity by insertion of specific mini-peptide-coding sequences. Cancer Gene Ther 17: 131-140.
21. Stoff-Khalili, MA, Rivera, AA, Nedeljkovic-Kurepa, A, DeBenedetti, A, Li, XL, Odaka, Y et al. (2008). Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control. Breast Cancer Res Treat 108: 43-55. (Pubitemid 351623247)
22. Corti, A, Curnis, F, Arap, W and Pasqualini, R (2008). The neovasculature homing motif NGR: more than meets the eye. Blood 112: 2628-2635.
23. Temming, K, Schiffelers, RM, Molema, G and Kok, RJ (2005). RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 8: 381-402. (Pubitemid 43358061)
24. Garanger, E, Boturyn, D, Jin, Z, Dumy, P, Favrot, MC and Coll, JL (2005). New multifunctional molecular conjugate vector for targeting, imaging, and therapy of tumors. Mol Ther 12: 1168-1175. (Pubitemid 41723051)
25. Huet, D, Bagot, M, Loyaux, D, Capdevielle, J, Conraux, L, Ferrara, P et al. (2006). SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells. J Immunol 176: 652-659. (Pubitemid 43023314)
26. Bhattacharya, R, Gonzalez, AM, Debiase, PJ, Trejo, HE, Goldman, RD, Flitney, FW et al. (2009). Recruitment of vimentin to the cell surface by beta3 integrin and plectin mediates adhesion strength. J Cell Sci 122(Pt 9): 1390-1400.
27. Creighton, CJ, Li, X, Landis, M, Dixon, JM, Neumeister, VM, Sjolund, A et al. (2009). Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106: 13820-13825.
28. Thiery, JP (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
29. Gilles, C, Polette, M, Zahm, JM, Tournier, JM, Volders, L, Foidart, JM et al. (1999). Vimentin contributes to human mammary epithelial cell migration. J Cell Sci 112 (Pt 24): 4615-4625. (Pubitemid 30034810)
30. Nieminen, M, Henttinen, T, Merinen, M, Marttila-Ichihara, F, Eriksson, JE and Jalkanen, S (2006). Vimentin function in lymphocyte adhesion and transcellular migration. Nat Cell Biol 8: 156-162.
31. Sancey, L, Lucie, S, Garanger, E, Elisabeth, G, Foillard, S, Stéphanie, F et al. (2009). Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol Ther 17: 837-843.
32. Gafner, V, Trachsel, E and Neri, D (2006). An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer 119: 2205-2212. (Pubitemid 44423682)
33. Gafner, S, Dietz, BM, McPhail, KL, Scott, IM, Glinski, JA, Russell, FE et al. (2006). Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2- (di-N-propylamino)tetralin to 5-HT1A receptors in Vitro. J Nat Prod 69: 432-435.
34. Zhu, S, Lee, DA and Li, S (2010). IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol 184: 2348-2354.